Incannex Receives Ethics Approval for Bioequivalence/Bioavailability Clinical Trial for IHL-42X, the Company’s Proprietary Drug for Treatment of Obstructive Sleep Apnoea (‘OSA’)
06 juil. 2023 08h42 HE
|
Incannex Healthcare
Highlights: Incannex has received approval from Bellberry Human Research Ethics Committee (‘HREC’) to commence the bioavailability/bioequivalence (‘BA/BE’) clinical trial to assess the...
Greenhouse Treatment Center Introduces Treatment Track Dedicated to Young Adults
05 juil. 2023 14h03 HE
|
Greenhouse Treatment Center
GRAND PRAIRIE, Texas, July 05, 2023 (GLOBE NEWSWIRE) -- Greenhouse Treatment Center, a leading provider of co-occurring mental health and substance use disorder treatment services, has announced the...
Oxford Treatment Center Issues Warning on Increasing Presence of Xylazine
05 juil. 2023 13h52 HE
|
Oxford Treatment Center
OXFORD, Miss., July 05, 2023 (GLOBE NEWSWIRE) -- Oxford Treatment Center, a leading provider of substance use and co-occurring mental health treatment in Mississippi, is warning residents about the...
All Rise Expands Treatment Court Model to Lead Comprehensive Justice System Reform
23 juin 2023 11h00 HE
|
All Rise
Alexandria, VA, June 23, 2023 (GLOBE NEWSWIRE) -- After nearly 30 years of leading the treatment court movement, the National Association of Drug Court Professionals (NADCP) announced today that the...
Incannex Announces Participation at the H.C. Wainwright 4th Annual Neuropsychiatry Virtual Conference June 26, 2023
23 juin 2023 08h00 HE
|
Incannex Healthcare
MELBOURNE, Australia, June 23, 2023 (GLOBE NEWSWIRE) -- Incannex Healthcare Limited (Nasdaq: IXHL) (ASX: IHL), (‘Incannex’ or the ‘Company’) a pharmaceutical company developing medicinal cannabinoid...
Recovery First Treatment Center Issues Warning on Presence of Xylazine
20 juin 2023 12h04 HE
|
Recovery First Treatment Center
HOLLYWOOD, Fla., June 20, 2023 (GLOBE NEWSWIRE) -- Recovery First Treatment Center, a leading provider of substance use and co-occurring mental health treatment, is warning residents about the...
Incannex Appoints Principal Investigators for IHL-42X Phase 2/3 Clinical Trial
16 juin 2023 08h00 HE
|
Incannex Healthcare
MELBOURNE, Australia, June 16, 2023 (GLOBE NEWSWIRE) -- Incannex Healthcare Limited (Nasdaq: IXHL) (ASX: IHL), (‘Incannex’ or the ‘Company’) a clinical-stage pharmaceutical company developing unique...
Global Substance Abuse Treatment Market Review and Forecast to 2030: Alcohol Addiction Commanded the Largest Market Share of 34.27% in 2022, Followed by Nicotine Addiction
09 juin 2023 07h23 HE
|
Research and Markets
Dublin, June 09, 2023 (GLOBE NEWSWIRE) -- The "Global Substance Abuse Treatment Market by Substance Abuse Type (Alcohol Addiction, Cocaine, Marijuana), Product (Behavioral Treatment, Drugs),...
Addiction Disorders Drugs (Alcohol, Marijuana, Prescription, OTC Meds): ~$25B Global Market Landscape 2023-2030 Featuring Profiles of Accord Healthcare, Insys Therapeutics, Purdue Pharma, and 34 Others
09 juin 2023 07h18 HE
|
Research and Markets
Dublin, June 09, 2023 (GLOBE NEWSWIRE) -- The "Global Addiction Disorders Drugs Market by Drug Type (Alcohol, Marijuana, Prescription & Over-the-Counter Medications), Treatment (Counseling &...
American Addiction Centers’ Online Talk Show Wins Telly Award a Second Year in a Row
06 juin 2023 16h08 HE
|
American Addiction Centers, Inc.
BRENTWOOD, Tenn., June 06, 2023 (GLOBE NEWSWIRE) -- “Addiction Talk Live,” a groundbreaking online talk show hosted by American Addiction Centers (AAC), has won a 2023 Telly Award for unscripted web...